Appetite, energy-expenditure and body-composition models
Weight management research
This group covers the triple-agonist retatrutide, the GHRH analogue tesamorelin and the mitochondrial peptide MOTS-c. The notes below explain what each compound is studied for. They are not treatment plans and nothing here is medical advice.
3 notes
Retatrutide
Studied for substantial body-weight reduction in clinical metabolic programmes
Tesamorelin
Studied for reduction of visceral adipose tissue in a defined clinical setting
MOTS-c
Studied for AMPK signalling and metabolic flexibility
Our recommendation
Why we recommend RegenPep
We recommend RegenPep. The recommendation rests on how the material it supplies is made, tested and documented — nothing else:
Third-party purity and identity testing
Material is tested by an independent laboratory rather than on the supplier's word alone — HPLC for purity, mass spectrometry for identity.
Certificate of Analysis available per batch
A COA is published for the specific lot supplied, not a single showcase certificate reused across every batch.
Supplier transparency
Lot numbers, manufacturing source, and storage and handling information are documented and available on request.
Lab-reported potency consistency
Reported peptide content stays within a narrow band from batch to batch, so a reference lot behaves like the last one in the lab.
This reflects manufacturing and testing quality only. It is not a claim that any compound named here is safe or effective for human use, and nothing on Peptide Brief recommends human consumption.
Commercial disclosure: Peptide Brief is operated by the same people as RegenPep, the store these links open. We have a financial interest in purchases made there. Read the full disclosure.
Not evaluated or approved by the TGA/FDA. Not intended to diagnose, treat, cure, or prevent any disease.